2022 journal article

Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasms

MOLECULAR THERAPY, 30(1), 295–310.

By: D. Snider n, G. Arthur n, G. Falduto*, A. Olivera*, L. Ehrhardt-Humbert n, E. Smith n, C. Smith n, D. Metcalfe*, G. Cruse n

Contributors: D. Snider n, G. Arthur n, G. Falduto*, A. Olivera*, L. Ehrhardt-Humbert n, E. Smith n, C. Smith n, D. Metcalfe*, G. Cruse n

MeSH headings : Humans; Mast Cells / metabolism; Mast Cells / pathology; Mastocytosis / genetics; Mastocytosis / pathology; Mastocytosis / therapy; Proto-Oncogene Proteins c-kit / genetics; RNA, Messenger / genetics; RNA, Messenger / metabolism; Receptor Protein-Tyrosine Kinases / metabolism
TL;DR: It is proposed that the innovative approach, which employs well-tolerated, chemically stable oligonucleotides to target KIT expression through unconventional pathways, has potential as a KIT-targeted therapeutic alone, or in combination with agents thattarget KIT signaling, in the treatment of K IT-associated malignancies. (via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being (Web of Science; OpenAlex)
Sources: Web Of Science, NC State University Libraries, ORCID
Added: February 7, 2022

Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.

Certain data included herein are derived from the Web of Science© and InCites© (2024) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.